Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Corso Svizzera 164, Turin, 10149, Italy.
Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital ASL Città di Torino, Turin, Italy.
Virol J. 2023 Jun 13;20(1):123. doi: 10.1186/s12985-023-02086-z.
Elite controllers are able to control viral replication without antiretroviral therapy. Exceptional elite controllers do not show disease progression for more than 25 years. Different mechanisms have been proposed and several elements of both innate and adaptive immunity are implicated. Vaccines are immune stimulating agents that can promote HIV-RNA transcription; transient plasma HIV-RNA detectability has been described within 7-14 days after different vaccinations. The most reliable mechanism involved in virosuppressed people living with HIV is a generalized inflammatory response that activates bystander cells harboring latent HIV. So far no data about viral load increase in elite controllers after SARS-CoV-2 vaccination are reported in literature.
We report the case of a 65-year-old woman of European ancestry, diagnosed with HIV-1/HCV co-infection more than 25 years ago. Since then, HIV-RNA remained undetectable and she never received ARV therapy. In 2021 she was vaccinated with mRNA-BNT162b2 vaccine (Pfizer-BioNTech®). She was administered with three doses in June, July and October 2021, respectively. The last available viral load was undetectable in March 2021. We observed an increase of VL at 32 cp/ml and 124 cp/mL, two and seven months after the second vaccine dose, respectively. During monthly follow-up, HIV-RNA gradually and spontaneously dropped becoming undetectable without ARV intervention. COVID-19 serology was positive with IgG 535 BAU/mL, showing response to vaccination. We measured total HIV-DNA at different time-points and we found it detectable both at the time of the higher plasma HIV-RNA (30 cp/10^6 PBMCs) and when it was undetectable (13 cp/10^6 PBMCs), in reduction.
This case is the first report, to our knowledge, describing a rebound of plasma HIV-RNA in an elite controller after three doses of mRNA-BNT162b2 vaccine for SARS-CoV-2. Concomitantly with a spontaneous reduction of plasma HIV-RNA ten months after the third dose of mRNA-BNT162b2 vaccine (Pfizer-BioNTech®) without antiretroviral therapy intervention, we observed a reduction of total HIV-DNA in peripheral mononuclear cells. The potential role of vaccinations in altering HIV reservoir, even in elite controllers when plasma HIV-RNA is undetectable, could be a valuable aspect to take into account for the future HIV eradication interventions.
精英控制者能够在没有抗逆转录病毒治疗的情况下控制病毒复制。极少数精英控制者在 25 年以上的时间里没有出现疾病进展。已经提出了不同的机制,先天和适应性免疫的几个因素都与之相关。疫苗是免疫刺激剂,可以促进 HIV-RNA 转录;在接受不同疫苗接种后 7-14 天内,可检测到短暂的血浆 HIV-RNA。在接受抗逆转录病毒治疗的 HIV 感染者中,最可靠的抑制病毒机制是一种全身性炎症反应,它激活潜伏 HIV 的旁观者细胞。迄今为止,文献中尚无关于接种 SARS-CoV-2 疫苗后精英控制者病毒载量增加的报道。
我们报告了一例 65 岁的欧洲裔女性,25 年前诊断为 HIV-1/HCV 合并感染。从那时起,HIV-RNA 一直无法检测到,她从未接受过抗逆转录病毒治疗。2021 年,她接种了 mRNA-BNT162b2 疫苗(辉瑞-生物技术公司)。她分别于 2021 年 6 月、7 月和 10 月接种了三剂疫苗。最后一次可检测到的病毒载量是在 2021 年 3 月。我们观察到在第二次疫苗接种后两个月和七个月时,VL 分别增加到 32 cp/ml 和 124 cp/ml。在每月的随访中,HIV-RNA 逐渐自发下降,无需抗逆转录病毒干预即可检测不到。COVID-19 血清学呈阳性,IgG 为 535 BAU/ml,表明疫苗接种有反应。我们在不同时间点测量了总 HIV-DNA,结果发现它在血浆 HIV-RNA 较高时(30 cp/10^6 PBMCs)和检测不到时(13 cp/10^6 PBMCs)均有检出,并且呈下降趋势。
这是首例已知描述在接受三剂 mRNA-BNT162b2 疫苗(辉瑞-生物技术公司)用于 SARS-CoV-2 接种后,精英控制者血浆 HIV-RNA 反弹的病例。在接受 mRNA-BNT162b2 疫苗(辉瑞-生物技术公司)第三次接种后十个月,血浆 HIV-RNA 自发下降,无需抗逆转录病毒治疗干预,同时我们观察到外周血单个核细胞中总 HIV-DNA 减少。疫苗接种在改变 HIV 储存库方面的潜在作用,即使在精英控制者血浆 HIV-RNA 无法检测到的情况下,也可能是未来 HIV 根除干预措施中值得考虑的一个方面。